Cost-effective policies for cervical cancer screening: An international review

PharmacoEconomics

Volumn 9, Issue 3, 1996, Pages 211-230

  Fahs, Marianne C ^a,d   Plichta, Stacey B ^b,d   Mandelblatt, Jeanne S ^c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b OLD DOMINION UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; BEHAVIOR; CANCER SCREENING; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; MEDICAL RESEARCH; MORBIDITY; MORTALITY; ORGANIZATION; PAPANICOLAOU TEST; POLICY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UTERINE CERVIX CANCER;

EID: 0030000329     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199609030-00004     Document Type: Review

References (109)

1. US Congress, Office of Technology Assessment. The costs and effectiveness of screening for cervical cancer in elderly women: background paper [OTA-BP-H-65]. Washington, DC: US Government Printing Office, 1990
2. Coleman MP, Esteve J, Damiecki P, et al. Trends in cancer incidence and mortality. Lyon: International Agency for Research on Cancer Scientific Publishing, 1993
3. Cellantano DD, de Lissovoy G. Assessment of cervical cancer screening and follow-up programs. Public Health Rev 1989/90; 17: 173-240
4. Dewar MA, Hall K, Perchalski J. Cervical cancer screening: past success and future challenge. Prim Care 1992; 19: 589-606
5. Fowler J. Screening for cervical cancer: current terminology, classification, and technique. Postgrad Med 1993; 93: 57-70
6. Hakama M. Potential contribution of screening to cancer mortality reduction. Cancer Detect Prev 1993; 17: 513-20
7. van der Graaf Y, Vooijs GP, Zielhuis GA. Cervical cancer screening revisited. Acta Cytol 1990; 34: 366-72
8. Mahlck CG, Jonsson H, Lenner P. Pap smear screening and changes in cervical cancer mortality in Sweden. Int J Gynaecol Obstet 1994; 44: 267-72
9. Parkin DM, Moss SM. An evaluation of screening policies for cervical cancer in England and Wales using a computer simulation model. J Epidemiol Community Health 1986; 40: 143-53
10. US Department of Health and Human Services. Clinician's handbook of preventive services. Washington, DC: US Government Printing Office, 1994
11. D'Epiro P. Periodic health evaluation: what to include in the evaluation. Patient Care 1993; 28: 14-28
12. Schiffman MH. Epidemiology of cervical human papillomavirus infections. Curr Top Microbiol Immunol 1994; 186: 55-81
13. Mandelblatt J, Schechter C, Fahs M, et al. Clinical implications of screening for cervical cancer under Medicare. The natural history of cervical cancer in the elderly: what do we know? What do we need to know? J Obstet Gynecol 1991 Feb; 164 (2): 644-51
14. Mandelblatt JS, Fahs M, Garibaldi K, et al. Association between HIV infection and cervical neoplasia: implications for clinical care of women at risk for both conditions. AIDS 1992; 6: 173-8
15. Petersen O. Spontaneous course of cervical precancerous conditions. Am J Obstet Gynecol 1956; 72: 1063-71
16. Fox CH. Time necessary for conversion of normal to dysplastic cervical epithelium. Obstet Gynecol 1968; 31: 749-54
17. Kashgarian M, Dunn JE. The duration of intraepithelial and preclinical squamous cell carcinoma of the uterine cervix. Am J Epidemiol 1970; 92: 211-22
18. Norman SA, Talbott EO, Kuller LH, et al. The relationship of Papanicolaou testing and contacts with the medical care system to stage at diagnosis of cervical cancer. Arch Intern Med 1991; 151: 58-64
19. Anon. Hysterectomy prevalence and death rates for cervical cancer: United States, 1965-1988. MMWR Morb Mortal Wkly Rep 1992; 41: 17-20
20. Munoz N, Bosch FX. HPV and cervical neoplasia: review of case-control and cohort studies. In: Munoz N, Bosch FX, Shah KV, et al., editors. The epidemiology of cervical cancer and human papillomavirus. Lyon: International Agency for Research on Cancer Scientific Publishing, 1992
21. Brinton LA. Epidemiology of cervical cancer: overview. In: Munoz N, Bosch FX, Shah KV, et al., editors. The epidemiology of cervical cancer and human papillomavirus. Lyon: International Agency for Research on Cancer Scientific Publishing, 1992
22. Meisels A, Morin C. Human papillomavirus and cancer of the uterine cervix. Gynecol Oncol 1981; 12 (2 Pt 2): S110-23
23. Reeves WC, Brinton LA, Garcia M, et al. Human papillomavirus infection and cervical cancer in Latin America. N Engl J Med 1989; 320: 1437-41
24. Eluf-Neto J, Booth M, Munoz N, et al. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994; 69: 114-9
25. Brinton LA, Herrero R, Reeves WC, et al. Risk factors for cervical cancer by histology. Gynecol Oncol 1993; 51: 301-6
26. Grubb GS. Human papillomavirus and cervical neoplasia: epidemiologic considerations. Int J Epidemiol 1986; 15: 1-7
27. Macnab JCM, Walkinshaw SA, Cordiner JW, et al. Human papillomavirus in clinically ami histologically normal tissue of patients with genital cancer. N Engl J Med 1986; 315: 1052-8
28. Meanwell CA, Cox MF, Blackledge G, et al. HPV 16 DNA in normal and malignant cervical epithelium: implications for the aetiology and behaviour of cervical neoplasia. Lancet 1987; i: 703-7
29. WHO. World health statistics annual. Geneva: WHO, 1988-1992
30. Mandelblatt J, Andrews H, Kerner J, et al. Determinants of late stage diagnosis of breast and cervical cancer: the impact of age, race, social class and hospital type. Am J Public Health 1991; 81: 646-9
31. Heckler MM. Report of the secretary's task force on Black and minority health: vol. I. Executive summary. Washington, DC: LS Government Printing Office, 1985
32. Frey CM. Cervix uteri, section V. In: Miller BA, Ries LAG, Hankey BF, et al., editors. Cancer statistics review 1973-1989. Washington, DC: US Government Printing Office, 1992
33. Parkin DM, Muir CS, Whelan YT, et al., editors. Cancer incidence in five continents: vol. VI. Lyon: International Agency of Research on Cancer Scientific Publishing, 1992
34. McWhorter WO, Schatzkin AG, Horn JW, et al. Contribution of socioeconomic status to Black/White differences in cancer incidence. Cancer 1989; 63: 982-7
35. Baquet CR, Horn JW, Gibbs T, et al. Socioeconomic factors and cancer incidence among Blacks and Whites. J Natl Cancer Inst 1991; 83: 551-7
36. Samelson EJ, Speers MA, Ferguson R. et al. Racial differences in cervical cancer mortality in Chicago. Am J Public Health 1994; 84: 1007-9
37. Chen F, Trapido ET, Davis K. Differences in stage at presentation of breast and gynecologic cancers among Whites, Blacks, and Hispanics. Cancer 1994; 73: 2838-42
38. Anon. Black-White differences in cervical cancer mortality: United States, 1980-1987. MMWR Morh Mortal Wkly Rep 1990; 39: 245-8
39. Siegel PZ, Frazier EL, Mariolis P, et al. Behavioral risk factor surveillance, 1991: monitoring progress toward the nation's year 2000 health objectives. MMWR Morb Mortal Wkly Rep 1993; 42 (4): 1-21
40. Wilcox LS, Mosher WD. Factors associated with obtaining health screening among women of reproductive age. Public Health Rep 1993; 108: 76-85
41. Dawson DA, Hendershaf GE, Bloom B. Trends in routine screening examinations. Am J Public Health 1987; 77: 1004-5
42. Peters RK, Bear MB, Thomas D. Barriers to screening for cancer of the cervix. Prev Med 1989; 18: 133-46
43. Suarez L, Lloyd L, Weiss N, et al. Effect of social networks on cancer-screening behavior of older Mexican-American women. J Natl Cancer Inst 1994; 86: 775-9
44. Council on Ethical and Judicial Affairs. Black-White disparities in health care. JAMA 1990; 263: 2344-6
45. Brinton LA, Fraumeni FJ. Epidemiology of uterine cervical cancer. J Chron Dis 1986; 39: 1051-65
46. Lambert B, Morisset R, Bielmann P. An etiologic survey of clinical factors in cervical intraepithelial neoplasia: a transverse retrospective study. J Reprod Med 1980; 24: 26-31
47. Graham S, Schotz W. Epidemiology of cancer of the cervix in Buffalo, New York. J Natl Cancer Inst 1979; 63: 23-7
48. Kessler II, Kulcar Z, Zimolo A, et al. Cervical cancer in Yugoslavia: II. Fpidemiological factors of possible etiologic significance. J Natl Cancer Inst 1974; 53: 51-60
49. Rotkin ID. A comparison review of key epidemiological studies in cervical cancer related to current searches for transmissible agents. Cancer Res 1973; 33: 1353-67
50. Williams MA, Kenya PR, Mati JKG, et al. Risk factors for cervical cancer in Kenyan women. Int J Epidemiol 1994; 23: 906-12
51. Hulka BS. Risk factors for cervical cancer. J Chron Dis 1982; 35: 3-9
52. Rellihan MA, Dooley DP, Burke TW, et al. Rapidly progressing cervical cancer in a patient with human immunodeficiency virus infection. Gynecol Oncol 1990; 36: 435-8
53. Monfardini S, Vaccher E, Pizzocaro G, et al. Unusual malignant tumors in 49 patients with HIV infection. AIDS 1989; 3: 449-52
54. Stratton P, Ciacco KH. Cervical neoplasia in the patient with HIV infection. Curr Opin Obstet Gynecol 1994; 6: 86-91
55. Rojel J. The interrelation between uterine cancer and syphilis. Acta Path Microbiol Scand 1953; S97: 11-78
56. Brinton LA, Schairer C, Haenszel W, et al. Smoking and invasive cervical cancer. JAMA 1986; 255: 3265-9
57. Cellantano DD, Klassen AC, Weisman CS, et al. Cervical cancer screening practices among older women: results from the Maryland cervical cancer case-control study. J Clin Epidemiol 1988; 41: 531-41
58. LaVecchia C, Decarli A, Gallus G. Epidemiology data on cervical carcinoma relevant to cytopathology. Appl Pathol 1987; 5: 25-32
59. Macgregor JE, Campbell MK, Mann EMF, et al. Screening for cervical intraepithelial neoplasia in North East Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease. BMJ 1994; 308: 1407-11
60. Slater DN, Milner PC, Radley H. Audit of deaths from cervical cancer: proposal for an essential component of the national screening programme. J Clin Pathol 1994; 47: 27-8
61. Eddy DM. Screening for cervical cancer. Ann Intern Med 1990; 113: 214-26
62. Benedet JL, Anderson MB, Matisic JP. A comprehensive program for cervical cancer detection and management. Am J Obstet Gynecol 1992; 166: 1254-9
63. Parkin DM, Ngyen-Dinh X, Day NE. The impact of screening on the incidence of cervical cancer in England and Wales. Br J Obstet Gynaecol 1985; 92: 150-7
64. Aareleid T, Pukkala E, Thomson H, et al. Cervical cancer incidence and mortality trends in Finland and Estonia: a screened vs an unscreened population. Eur J Cancer 1993; 29A: 745-9
65. Adami HO, Ponten J, Sparen P, et al. Survival trend after invasive cancer diagnosis in Sweden before and after cytologic screening. Cancer 1994; 73: 140-7
66. Hollard BK, Foster JD, Louria DB. Cervical cancer and health care resources in Newark, New Jersey, 1970-1988. Am J Public Health 1993; 83: 45-8
67. Weisbrod BA. Redistribution efforts and benefit-cost analysis. In: Chase SB, editor. Problems of public expenditure analysis. Washington, DC: The Brookings Institution, 1968: 177-209
68. Mishan EJ. Cost benefit analysis. New York: Praeger, 1973
69. Birch S, Gafni A. Cost-effectiveness/utility analyses: do current decision rules lead us to where we want to be? J Health Econ 1992; 11: 279-96
70. Jacobs P. The economics of health and medical care. 2nd ed. Rockville (MD): Aspen Publishers, 1987
71. Sorkin AL. Health economics: an introduction. 2nd ed. Lexington (KY): DC Health and Company, 1984
72. Johannesson M, Jönsson B. Economic evaluation in health care: is there a role for cost-benefit analysis? Health Policy 1991; 17: 1-23
73. Marin A. Commodity, the bias of the world. Sci Total Environ 1986; 56: 77-87
74. Donaldson M. Willingness-to-pay for publicly provided goods: a possible measure of benefit? J Health Econ 1990; 9: 103-18
75. Thompson MS, Read JL, Liang M. Feasibility of willingness-to-pay measurement in chronic arthritis. Med Decis Making 1984; 4: 195-215
76. Fahs MC, Garibaldi K. Relationships among insurance coverage, access to services and health outcomes: case study of cervical cancer and African-American women. Office of Technology Assessment, US Congress. Washington, DC: US Printing Office, 1992 Apr
77. Cull A, Cowie VJ, Farquharson DIM, et al. Early stage cervical cancer: psychosocial and sexual outcomes of treatment. Br J Cancer 1993; 68: 1216-20
78. Valente S. Urological problems and quality of life after treatment in early cervical cancer. Eur J Gynaecol Oncol 1966; 9: 424-7
79. Bethwaite MA, Rayner T, Bethwaite P. Economic aspects of screening for cervical cancer in New Zealand. N Z Med J 1986; 99: 747-51
80. Fahs MC, Mandelblatt J, Schlechter C, et al. Cost-effectiveness of cervical cancer screening for the elderly. Ann Intern Med 1992; 117: 520-7
81. Gustafsson L, Adami HO. Optimization of cervical cancer screening. Cancer Causes Control 1992; 3: 125-36
82. Koopmanschap M, Lubbe KT, van Oortmarssen GJ, et al. Economic aspects of cervical cancer screening. Soc Sci Med 1990; 30: 1081-7
83. Sherlaw-Johnson C, Gallivan S, Jenkins D, et al. Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modeling. J Clin Pathol 1994; 47: 430-5
84. van Ballegooijen M, Habbema JDF, van Oortmarssen GJ, et al. Preventive Pap smears: balancing costs, risks and benefits. Br J Cancer 1992; 65: 930-3
85. Te Velde ER, Habbema JD, Gelpke GJ, et al. Prognostic significance of pretreatment variables in patients with invasive cervical cancer. Eur J Cancer Clin Oncol 1987 Sep; 23 (9): 1357-64
86. Takenaja N, Kai I, Ohi G. Evaluation of three cervical cancer detection programs in Japan with special reference to cost-benefit analysis. Cancer 1985; 55: 2514-9
87. Lynge E, Arffmann E, Poll P, et al. Smear misclassification in a cervical cancer screening program. Br J Cancer 1993; 68: 368-73
88. van Oortmarssen GJ, Habbema JDF, van Ballegooijen M. Predicting mortality from cervical cancer after negative smear test results. BMJ 1992; 305: 449-51
89. Mandelblatt JS, Fahs MC. The cost-effectiveness of cervical cancer screening in low income elderly women. JAMA 1988; 259: 2409-13
90. Shrivshav P, Jairaj P, Balasubramaniam N, et al. Selective screening for carcinoma cervix in Souih Indian women. Int J Gynaecol Obstet 1986; 24: 337-42
91. Prabhakar AK. Cervical cancer in India - strategy for control. Indian J Cancer 1992; 29: 104-13
92. Murthy NS, Agarwal SS, Prabhakar AK, et al. Estimation of reduction of life-time risk of cervical cancer through one life-time screening. Neoplasma 1993; 40: 255-8
93. Johnson N, Sutton J, Thornton JG, et al. Decision analysis for best management of mildly dyskaryotic smear. Lancet 1993; 342: 91-6
94. Reid R, Greenberg MD, Lorincz A, et al. Should cervical cytological testing be augmented by cervicography or human papillomavirus deoxyribonucleic acid detection? Am J Obstet Gynecol 1991; 164 (6 Pt 1): 1461-9
95. Helfand M, O'Connor GR, Zimmer-Gembeck M, et al. Effect of the clinical laboratory amendments of 1988 (CLA '88) on the incidence of invasive cervical cancer. Med Care 1992; 30: 1067-82
96. Koopmanschap MA, Rutten FFH, van Inveled BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171-89
97. Fahs MC. Preventive medical care: targeting women in an aging society. In: Allen J, Pifer A, editors. Women on the front lines. Washington, DC: The Urban Institute Press, 1993
98. Tavelli BG, Judson FN, Hetrich AE, et al. Cost-yield of routine Papanicolaou smear screening in a clinic for sexually transmitted diseases. Sex Transm Dis 1985; 12; 110-3
99. Mandelblatt J, Traxler M, Lakin P, et al. Breast and cervical cancer screening of poor, elderly, Black women: clinical results and implications. Harlem Study Team. Am J Prev Med 1993; 9: 133-8
100. Anon. Results from the national breast and cervical cancer early detection program: October 31, 1991 - September 30, 1993. MMWR Morb Mortal Wkly Rep 1994; 43: 530-4
101. Curtis P, Varenhold JJ, Skinner B, et al. Development of a Pap smear quality assurance system in family practice. Fam Med 1993; 25: 135-9
102. Banda-Gamboa H, Ricketts I, Cairns A, et al. Automation in cervical cytology: an overview. Anal Cell Pathol 1992; 4: 25-48
103. Stenkvist B, Strande G. Analysis of machine selected cells with an image analysis system in normal and abnormal cervical specimens. Anal Cell Pathol 1989; 2: 1-13
104. Tawa K, Forsythe A, Cove JK, et al. A comparison of the Papanicolaou smear and the cervigram: sensitivity, specificity, and cost analysis. Obstet Gynecol 1988; 71: 229-35
105. Mann W, Lanky N, Massad S, et al. Papanicolaou smear screen augmented by a magnified chemiluminescent exam. Int J Gynaecol Obstet 1993; 43: 289-96
106. Garland SM, Faulkner-Jones BE, Fortune DW, et al. Cervical cancer - what role for human papilloma virus? Med J Aust 1992; 156: 204-12
107. Manfredi C, Lacey L, Warnecke R. Results of an intervention to improve compliance with referrals for evaluation of suspected malignancies at neighborhood public health centers. Am J Public Health 1990; 80: 85-7
108. Marcus AC, Crane LA, Kaplan CP, et al. Improving adherence to screening follow-up among women with abnormal Pap smears. Med Care 1992; 30: 216-30
109. Paskett ED, White E, Carter W, et al. Improving follow-up after an abnormal Pap: a randomized controlled trial. Prev Med 1990; 19: 630-41